Switch to:
Also traded in: Argentina, Brazil, Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 0.94
NYSE:BMY's Cash-to-Debt is ranked lower than
62% of the 859 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.03 vs. NYSE:BMY: 0.94 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:BMY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.32  Med: 0.94 Max: 3.88
Current: 0.94
0.32
3.88
Equity-to-Asset 0.40
NYSE:BMY's Equity-to-Asset is ranked lower than
81% of the 788 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. NYSE:BMY: 0.40 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:BMY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.46 Max: 0.64
Current: 0.4
0.33
0.64
Debt-to-Equity 0.54
NYSE:BMY's Debt-to-Equity is ranked lower than
69% of the 596 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.32 vs. NYSE:BMY: 0.54 )
Ranked among companies with meaningful Debt-to-Equity only.
NYSE:BMY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.08  Med: 0.42 Max: 1.01
Current: 0.54
0.08
1.01
Debt-to-EBITDA 1.22
NYSE:BMY's Debt-to-EBITDA is ranked higher than
57% of the 495 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.92 vs. NYSE:BMY: 1.22 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NYSE:BMY' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.71  Med: 1.22 Max: 2.57
Current: 1.22
0.71
2.57
Interest Coverage 21.91
NYSE:BMY's Interest Coverage is ranked lower than
63% of the 648 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 86.08 vs. NYSE:BMY: 21.91 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:BMY' s Interest Coverage Range Over the Past 10 Years
Min: 8.44  Med: 19.6 Max: 45.77
Current: 21.91
8.44
45.77
Piotroski F-Score: 6
Altman Z-Score: 5.37
Beneish M-Score: -2.98
WACC vs ROIC
10.46%
8.12%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 18.50
NYSE:BMY's Operating Margin % is ranked higher than
75% of the 801 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.97 vs. NYSE:BMY: 18.50 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:BMY' s Operating Margin % Range Over the Past 10 Years
Min: 10.45  Med: 22.84 Max: 31.24
Current: 18.5
10.45
31.24
Net Margin % 6.50
NYSE:BMY's Net Margin % is ranked lower than
63% of the 802 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.32 vs. NYSE:BMY: 6.50 )
Ranked among companies with meaningful Net Margin % only.
NYSE:BMY' s Net Margin % Range Over the Past 10 Years
Min: 4.85  Med: 15.78 Max: 56.42
Current: 6.5
4.85
56.42
ROE % 10.97
NYSE:BMY's ROE % is ranked lower than
59% of the 832 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.94 vs. NYSE:BMY: 10.97 )
Ranked among companies with meaningful ROE % only.
NYSE:BMY' s ROE % Range Over the Past 10 Years
Min: 7.21  Med: 19.06 Max: 78.36
Current: 10.97
7.21
78.36
ROA % 4.29
NYSE:BMY's ROA % is ranked lower than
58% of the 871 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.88 vs. NYSE:BMY: 4.29 )
Ranked among companies with meaningful ROA % only.
NYSE:BMY' s ROA % Range Over the Past 10 Years
Min: 2.99  Med: 8.44 Max: 35.08
Current: 4.29
2.99
35.08
ROC (Joel Greenblatt) % 105.89
NYSE:BMY's ROC (Joel Greenblatt) % is ranked higher than
95% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 11.23 vs. NYSE:BMY: 105.89 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:BMY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 51.19  Med: 94.31 Max: 155.17
Current: 105.89
51.19
155.17
3-Year Revenue Growth Rate 9.80
NYSE:BMY's 3-Year Revenue Growth Rate is ranked higher than
65% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. NYSE:BMY: 9.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:BMY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -8.4  Med: 3.1 Max: 11.8
Current: 9.8
-8.4
11.8
3-Year EBITDA Growth Rate 26.50
NYSE:BMY's 3-Year EBITDA Growth Rate is ranked higher than
80% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. NYSE:BMY: 26.50 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:BMY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -26  Med: 7.8 Max: 26.5
Current: 26.5
-26
26.5
3-Year EPS without NRI Growth Rate -20.20
NYSE:BMY's 3-Year EPS without NRI Growth Rate is ranked lower than
84% of the 663 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. NYSE:BMY: -20.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:BMY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -22.9  Med: 5.4 Max: 30.7
Current: -20.2
-22.9
30.7
GuruFocus has detected 2 Warning Signs with Bristol-Myers Squibb Company NYSE:BMY.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:BMY's 30-Y Financials

Financials (Next Earnings Date: 2019-01-26 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2017

BMY Guru Trades in Q4 2017

Jeremy Grantham 10,700 sh (New)
Ken Fisher 582,213 sh (+15.41%)
Dodge & Cox 29,106,111 sh (+0.18%)
Joel Greenblatt 154,793 sh (+27.30%)
PRIMECAP Management 6,557,578 sh (+2.87%)
Steven Cohen 115,000 sh (+53.33%)
Jim Simons 14,302,900 sh (+31.87%)
Louis Moore Bacon 192,140 sh (+35.29%)
Pioneer Investments 2,797,167 sh (+108.99%)
First Eagle Investment 49,229 sh (unchged)
Kahn Brothers 19,050 sh (unchged)
Tom Gayner 10,000 sh (unchged)
Jeff Auxier 6,393 sh (unchged)
Frank Sands Sold Out
Vanguard Health Care Fund 48,534,812 sh (-4.26%)
Ronald Muhlenkamp 174,575 sh (-1.46%)
T Rowe Price Equity Income Fund 3,040,000 sh (-3.95%)
Murray Stahl 48,915 sh (-0.20%)
Spiros Segalas 8,520,616 sh (-12.43%)
Paul Tudor Jones 29,786 sh (-76.16%)
Mairs and Power 332,592 sh (-2.13%)
Mario Gabelli 408,602 sh (-12.67%)
Eaton Vance Worldwide Health Sciences Fund 565,824 sh (-5.33%)
» More
Q1 2018

BMY Guru Trades in Q1 2018

John Hussman 25,000 sh (New)
Caxton Associates 4,572 sh (New)
Leon Cooperman 468,000 sh (New)
Ronald Muhlenkamp 178,436 sh (+2.21%)
Kahn Brothers 19,750 sh (+3.67%)
PRIMECAP Management 16,430,950 sh (+150.56%)
Jeff Auxier 7,393 sh (+15.64%)
Paul Tudor Jones 68,575 sh (+130.23%)
Jim Simons 14,528,300 sh (+1.58%)
Mario Gabelli 466,179 sh (+14.09%)
Tom Gayner 10,000 sh (unchged)
Jeremy Grantham 10,700 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 565,824 sh (unchged)
First Eagle Investment Sold Out
Signature Select Canadian Fund Sold Out
Vanguard Health Care Fund 46,688,361 sh (-3.80%)
Ken Fisher 577,081 sh (-0.88%)
T Rowe Price Equity Income Fund 2,770,000 sh (-8.88%)
Dodge & Cox 27,817,611 sh (-4.43%)
Joel Greenblatt 23,077 sh (-85.09%)
Murray Stahl 47,115 sh (-3.68%)
Spiros Segalas 7,353,619 sh (-13.70%)
Steven Cohen 75,000 sh (-34.78%)
Mairs and Power 291,902 sh (-12.23%)
Louis Moore Bacon 178,083 sh (-7.32%)
Pioneer Investments 2,742,824 sh (-1.94%)
» More
Q2 2018

BMY Guru Trades in Q2 2018

Ray Dalio 273,634 sh (New)
Bill Nygren 6,500,000 sh (New)
Vanguard Health Care Fund 50,597,061 sh (+8.37%)
Ken Fisher 581,310 sh (+0.73%)
T Rowe Price Equity Income Fund 2,810,000 sh (+1.44%)
Dodge & Cox 32,705,086 sh (+17.57%)
Joel Greenblatt 296,301 sh (+1183.97%)
Kahn Brothers 19,950 sh (+1.01%)
PRIMECAP Management 18,043,794 sh (+9.82%)
Steven Cohen 3,416,898 sh (+4455.86%)
Paul Tudor Jones 86,718 sh (+26.46%)
Mario Gabelli 556,603 sh (+19.40%)
John Hussman 25,000 sh (unchged)
Jeremy Grantham 10,700 sh (unchged)
Ronald Muhlenkamp Sold Out
Tom Gayner Sold Out
Caxton Associates Sold Out
Louis Moore Bacon Sold Out
Leon Cooperman Sold Out
Murray Stahl 45,900 sh (-2.58%)
Spiros Segalas 4,746,444 sh (-35.45%)
Mairs and Power 278,944 sh (-4.44%)
Pioneer Investments 2,682,994 sh (-2.18%)
Eaton Vance Worldwide Health Sciences Fund 176,060 sh (-68.88%)
Jeff Auxier 7,269 sh (-1.68%)
Jim Simons 10,547,200 sh (-27.40%)
» More
Q3 2018

BMY Guru Trades in Q3 2018

Lee Ainslie 148,610 sh (New)
Spiros Segalas 6,315,776 sh (+33.06%)
PRIMECAP Management 18,906,694 sh (+4.78%)
Paul Tudor Jones 141,749 sh (+63.46%)
Dodge & Cox 32,969,186 sh (+0.81%)
Kahn Brothers 19,950 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 176,060 sh (unchged)
Jeff Auxier 7,269 sh (unchged)
Bill Nygren 6,500,000 sh (unchged)
John Hussman Sold Out
T Rowe Price Equity Income Fund 2,560,000 sh (-8.90%)
Ken Fisher 509,243 sh (-12.40%)
Vanguard Health Care Fund 49,971,861 sh (-1.24%)
Mario Gabelli 540,103 sh (-2.96%)
Ray Dalio 257,070 sh (-6.05%)
Jim Simons 9,344,000 sh (-11.41%)
Jeremy Grantham 7,600 sh (-28.97%)
Mairs and Power 256,531 sh (-8.03%)
Pioneer Investments 2,506,256 sh (-6.59%)
Murray Stahl 44,965 sh (-2.04%)
Joel Greenblatt 195,005 sh (-34.19%)
Steven Cohen 2,186,037 sh (-36.02%)
» More
» Details

Insider Trades

Latest Guru Trades with BMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

Guru Date Action
Impact Price Range
(Average)*
Change from Average Comment Current Shares
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Bristol-Myers Squibb Company

SymbolPriceYieldDescription
BMYMP.PFD890.950.22$2.00 Convertible Preferred Stock

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:LSE:AZN, NYSE:LLY, XPAR:SAN, LSE:GSK, XTER:BAYN, TSE:4503, TSE:4519, TSE:4578, TSE:4568, HKSE:01093, NYSE:ABBV, TSE:4151, TSE:4528, NYSE:MRK, SHSE:600436, SHSE:600867, SZSE:002422, MIL:REC, BOM:500087, BOM:500302 » details
Traded in other countries:BMY.Argentina, BMYB34.Brazil, BRM.Germany, BMY.Mexico, BMY.Switzerland, 0R1F.UK,
Headquarter Location:USA
Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceuticals products. The company operates in one segment that is Biopharmaceuticals.

Bristol-Myers Squibb discovers, develops, and markets drugs for various indications, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is leading in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded drugs.

Top Ranked Articles about Bristol-Myers Squibb Company

Investor Expectations to Drive Momentum within Bristol-Myers Squibb, Leaf Group, SendGrid, Exantas Capital, Under Armour, and Medley Management — Discovering Underlying Factors of Influence
Bristol-Myers Squibb's New Psoriasis Drug Has Echoes of Humira Humira became the best-selling drug of all time because it was the first fully human monoclonal antibody and treats so many disorders. Bristol-Myers' new psoriasis candidate has similar potential
Could Bristol-Myers Squibb (NYSE:BMY) be the one to come out with the next Humira? Probably not, but its new drug candidate for plaque psoriasis BMS-986165 at least has a shot to come within the same ballpark. For shareholders, that may be enough. Read more...
Bill Nygren’s Top 3 Buys in 2nd Quarter Oakmark Fund manager releases quarterly portfolio
Bill Nygren (Trades, Portfolio), portfolio manager of the Oakmark Fund, disclosed on Wednesday three new positions for the second quarter: Bristol-Myers Squibb Co. (NYSE:BMY), Gartner Inc. (NYSE:IT) and Hilton Worldwide Holdings Inc. (NYSE:HLT). Read more...
Ronald Muhlenkamp Dumps One Pharmaceutical Company in Favor of Another Guru releases 2nd-quarter portfolio
Ronald Muhlenkamp (Trades, Portfolio), leader of investment firm Muhlenkamp & Co. Inc., disclosed in his second-quarter portfolio that he exchanged his Bristol-Myers Squibb Co. (NYSE:BMY) holding for a position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ). Read more...
Bill Nygren Comments on Bristol-Myers Squibb Guru stock highlight
Bristol-Myers Squibb (NYSE:BMY) is a global biopharmaceutical company with leading franchises in oncology, immunoscience and cardiovascular drugs. Long-time shareholders may recall a successful Bristol-Myers Squibb investment that we sold in 2013. We got another opportunity to own this company during the past quarter when investors became fearful that a competing drug would take share in the cancer market. We believe these fears are overstated because cancer remains a dangerous disease that is difficult to treat. The company’s two most valuable drugs Opdivo and Yervoy should continue to grow revenue as they maintain effectiveness with new tumor types. Bristol Myers Squibb also has the most new molecular agents and the highest number of combinations of agents in trials. Moreover, the company’s R&D and marketing prowess also make it a desired partner for promising academic and small biotech innovators. Collectively, these assets should assure Bristol-Myers Squibb’s oncology leadership for many years. We believe intrinsic value is closer to the $70 level Read more...
Advantagene Announces Clinical Trial Collaboration
Bristol-Myers Squibb Stock Shareholder Alert - Kehoe Law Firm, P.C. Investigating
The Klein Law Firm Reminds Investors of a Class Action on Behalf of Bristol-Myers Squibb Company Shareholders and a Lead Plaintiff Deadline of April 10, 2018 (BMY)
BMY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Bristol-Myers Squibb Company and a Lead Plaintiff Deadline of April 10, 2018
GRYT Health and Bristol-Myers Squibb Announce New Digital Pilot to Advance Cancer Care through Patient-Driven Insights

Ratios

vs
industry
vs
history
PE Ratio 60.27
BMY's PE Ratio is ranked lower than
97% of the 557 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.77 vs. BMY: 60.27 )
Ranked among companies with meaningful PE Ratio only.
BMY' s PE Ratio Range Over the Past 10 Years
Min: 4.09  Med: 24.24 Max: 253.71
Current: 60.27
4.09
253.71
Forward PE Ratio 13.00
BMY's Forward PE Ratio is ranked higher than
64% of the 111 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.60 vs. BMY: 13.00 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 60.27
BMY's PE Ratio without NRI is ranked lower than
97% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 24.20 vs. BMY: 60.27 )
Ranked among companies with meaningful PE Ratio without NRI only.
BMY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.33  Med: 24.55 Max: 253.71
Current: 60.27
12.33
253.71
Price-to-Owner-Earnings 23.98
BMY's Price-to-Owner-Earnings is ranked higher than
58% of the 324 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 31.95 vs. BMY: 23.98 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BMY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.57  Med: 23.65 Max: 413.04
Current: 23.98
3.57
413.04
PB Ratio 6.42
BMY's PB Ratio is ranked lower than
87% of the 819 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.64 vs. BMY: 6.42 )
Ranked among companies with meaningful PB Ratio only.
BMY' s PB Ratio Range Over the Past 10 Years
Min: 2.46  Med: 5.09 Max: 9.54
Current: 6.42
2.46
9.54
PS Ratio 3.99
BMY's PS Ratio is ranked lower than
63% of the 775 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. BMY: 3.99 )
Ranked among companies with meaningful PS Ratio only.
BMY' s PS Ratio Range Over the Past 10 Years
Min: 1.62  Med: 4.05 Max: 7.25
Current: 3.99
1.62
7.25
Price-to-Free-Cash-Flow 23.67
BMY's Price-to-Free-Cash-Flow is ranked higher than
59% of the 298 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.84 vs. BMY: 23.67 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BMY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.41  Med: 19.83 Max: 375.94
Current: 23.67
7.41
375.94
Price-to-Operating-Cash-Flow 18.99
BMY's Price-to-Operating-Cash-Flow is ranked higher than
57% of the 392 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 22.00 vs. BMY: 18.99 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BMY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.93  Med: 14.73 Max: 97.02
Current: 18.99
6.93
97.02
EV-to-EBIT 16.48
BMY's EV-to-EBIT is ranked lower than
63% of the 572 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.85 vs. BMY: 16.48 )
Ranked among companies with meaningful EV-to-EBIT only.
BMY' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.2  Med: 16.3 Max: 126.7
Current: 16.48
6.2
126.7
EV-to-EBITDA 14.67
BMY's EV-to-EBITDA is ranked lower than
62% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.24 vs. BMY: 14.67 )
Ranked among companies with meaningful EV-to-EBITDA only.
BMY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.5  Med: 14.25 Max: 57.3
Current: 14.67
5.5
57.3
EV-to-Revenue 4.00
BMY's EV-to-Revenue is ranked lower than
61% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.24 vs. BMY: 4.00 )
Ranked among companies with meaningful EV-to-Revenue only.
BMY' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.6  Med: 4.15 Max: 7.4
Current: 4
1.6
7.4
PEG Ratio 4.19
BMY's PEG Ratio is ranked lower than
93% of the 317 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.93 vs. BMY: 4.19 )
Ranked among companies with meaningful PEG Ratio only.
BMY' s PEG Ratio Range Over the Past 10 Years
Min: 0.62  Med: 1.91 Max: 19.11
Current: 4.19
0.62
19.11
Shiller PE Ratio 23.96
BMY's Shiller PE Ratio is ranked higher than
62% of the 252 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.75 vs. BMY: 23.96 )
Ranked among companies with meaningful Shiller PE Ratio only.
BMY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 10.83  Med: 20.66 Max: 36.36
Current: 23.96
10.83
36.36
Current Ratio 1.53
BMY's Current Ratio is ranked lower than
73% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. BMY: 1.53 )
Ranked among companies with meaningful Current Ratio only.
BMY' s Current Ratio Range Over the Past 10 Years
Min: 1.13  Med: 1.63 Max: 2.32
Current: 1.53
1.13
2.32
Quick Ratio 1.40
BMY's Quick Ratio is ranked lower than
64% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.87 vs. BMY: 1.40 )
Ranked among companies with meaningful Quick Ratio only.
BMY' s Quick Ratio Range Over the Past 10 Years
Min: 0.93  Med: 1.4 Max: 2.06
Current: 1.4
0.93
2.06
Days Inventory 69.20
BMY's Days Inventory is ranked higher than
76% of the 755 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 119.80 vs. BMY: 69.20 )
Ranked among companies with meaningful Days Inventory only.
BMY' s Days Inventory Range Over the Past 10 Years
Min: 69.2  Med: 116.62 Max: 141.93
Current: 69.2
69.2
141.93
Days Sales Outstanding 76.55
BMY's Days Sales Outstanding is ranked higher than
57% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 81.76 vs. BMY: 76.55 )
Ranked among companies with meaningful Days Sales Outstanding only.
BMY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 35.38  Med: 48.27 Max: 76.55
Current: 76.55
35.38
76.55
Days Payable 99.41
BMY's Days Payable is ranked higher than
64% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 76.32 vs. BMY: 99.41 )
Ranked among companies with meaningful Days Payable only.
BMY' s Days Payable Range Over the Past 10 Years
Min: 99.41  Med: 141.65 Max: 230.86
Current: 99.41
99.41
230.86

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.98
BMY's Dividend Yield % is ranked higher than
76% of the 752 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. BMY: 2.98 )
Ranked among companies with meaningful Dividend Yield % only.
BMY' s Dividend Yield % Range Over the Past 10 Years
Min: 1.99  Med: 3.21 Max: 7.07
Current: 2.98
1.99
7.07
Dividend Payout Ratio 1.80
BMY's Dividend Payout Ratio is ranked lower than
99% of the 477 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.30 vs. BMY: 1.80 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BMY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.58  Med: 0.92 Max: 2.57
Current: 1.8
0.58
2.57
3-Year Dividend Growth Rate 2.70
BMY's 3-Year Dividend Growth Rate is ranked lower than
64% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. BMY: 2.70 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
BMY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 3 Max: 12.3
Current: 2.7
0
12.3
Forward Dividend Yield % 3.07
BMY's Forward Dividend Yield % is ranked higher than
74% of the 719 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.66 vs. BMY: 3.07 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 3.42
BMY's 5-Year Yield-on-Cost % is ranked higher than
69% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.12 vs. BMY: 3.42 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BMY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.28  Med: 3.69 Max: 8.12
Current: 3.42
2.28
8.12
3-Year Average Share Buyback Ratio 0.60
BMY's 3-Year Average Share Buyback Ratio is ranked higher than
92% of the 571 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -5.30 vs. BMY: 0.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BMY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.6  Med: 0.6 Max: 5.2
Current: 0.6
-0.6
5.2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 14.97
BMY's Price-to-Tangible-Book is ranked lower than
95% of the 749 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.33 vs. BMY: 14.97 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BMY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.16  Med: 12.24 Max: 53.46
Current: 14.97
4.16
53.46
Price-to-Intrinsic-Value-Projected-FCF 2.25
BMY's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
54% of the 374 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. BMY: 2.25 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BMY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.97  Med: 1.91 Max: 4.08
Current: 2.25
0.97
4.08
Price-to-Median-PS-Value 0.99
BMY's Price-to-Median-PS-Value is ranked lower than
71% of the 743 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.94 vs. BMY: 0.99 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BMY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.48  Med: 0.75 Max: 2.12
Current: 0.99
0.48
2.12
Price-to-Peter-Lynch-Fair-Value 3.95
BMY's Price-to-Peter-Lynch-Fair-Value is ranked lower than
98% of the 212 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.41 vs. BMY: 3.95 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
BMY' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.66  Med: 2.38 Max: 45.77
Current: 3.95
0.66
45.77
Price-to-Graham-Number 6.33
BMY's Price-to-Graham-Number is ranked lower than
99% of the 481 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.81 vs. BMY: 6.33 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BMY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.53  Med: 3.26 Max: 15.06
Current: 6.33
1.53
15.06
Earnings Yield (Greenblatt) % 6.07
BMY's Earnings Yield (Greenblatt) % is ranked higher than
59% of the 867 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.31 vs. BMY: 6.07 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BMY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.8  Med: 6.15 Max: 16.1
Current: 6.07
0.8
16.1
Forward Rate of Return (Yacktman) % 18.47
BMY's Forward Rate of Return (Yacktman) % is ranked higher than
95% of the 421 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.96 vs. BMY: 18.47 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BMY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -15  Med: 5.1 Max: 25.8
Current: 18.47
-15
25.8

More Statistics

Revenue (TTM) (Mil) $22,037.00
EPS (TTM) $ 0.89
Beta1.39
Volatility29.47%
52-Week Range $46.94 - 70.05
Shares Outstanding (Mil)1,632.20

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 22,474 23,862 25,446
EBIT (Mil $) 6,073 6,800 7,097
EBITDA (Mil $) 6,814 7,543 7,864
EPS ($) 2.92 3.84 4.08
EPS without NRI ($) 2.92 3.84 4.08
EPS Growth Rate
(Future 3Y To 5Y Estimate)
11.29%
Dividends per Share ($) 1.69 1.73 1.69

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

» More Articles for NYSE:BMY

Headlines

Articles On GuruFocus.com

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}